Search

Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Ribavirin

Additionally, including ribavirin in the regimen can increase the risk of anemia. … According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), ribavirin is typically used as an

Anagrelide

[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.

Tozinameran

[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein … [L15027] On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately

PPI-1019

Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

Potassium hydroxide

Potassium hydroxide, also known as _lye_ is an inorganic compound with the chemical formula _KOH_. … [L1943] In addition to the above uses, potassium hydroxide is also used in making soap, as an electrolyte in alkaline batteries and in electroplating, lithography, and paint and varnish removers.

Aluminum acetate

Cat dander extract

An allergic reaction to cats is induced by the presence of antigen-specific IgE antibodies that are bound to specific receptors on mast cells and basophils. … Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.

Anpocogin

Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

Natalizumab

[L48041] Natalizumab was approved by the European Commission on September 22, 2023.[L49096]